28 June 2013
IGOS is an international, observational, prospective, multi-center study including at least 1000 patients with Guillain-Barré syndrome. IGOS aims to identify the clinical and biological determinants and predictors of the clinical course of GBS and to personalize and improve the treatment.
GBS is an acute immune-mediated polyradiculoneuropathy with an exceptionally diverse clinical course and outcome. Some patients have some mild limitations and recover spontaneously. Others become fully paralysed within a few days and need to be ventilated at an ICU for months. Demographic factors, preceding infections, genetic polymorphisms, antibodies and other mediators, and clinical and electrophysiological characteristics may all play a role. In IGOS all these potential factors are documented or tested, in addition to the applied treatment strategies and clinical outcome.
Patients with all variants of GBS within 2 weeks of onset of weakness can be included, irrespective of age, disease severity and treatment. At standardized time points, during a follow up of 1-3 years, data and biomaterials will be collected. IGOS started in May 2012 and already 130 patients are included from 9 different countries. (United Kingdom, USA, Italy, The Netherlands, Denmark, Germany, Spain, Belgium, and Canada). At present more than 80 institutes are participating. We expect this number will increase since more centers are enlisting, including those from 6 other countries. The participants will collaborate in 12 different expertise groups each approaching a specific set of research questions, ranging from basic immunological mechanisms to long-term quality of life. We expect to finish the last inclusion within 3 years.
Colleagues interested to participate can still enlist. For more information please contact us via e-mail: email@example.com
Bianca van den Berg, Bart C. Jacobs
On behalf of the IGOS study group
Erasmus MC, University Medical Center Rotterdam